PubRank

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH)

Clinical Trial ID NCT00586391

PubWeight™ 32.95‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00586391

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010 3.57
2 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014 2.84
3 The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016 2.09
4 Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013 2.07
5 Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013 1.91
6 Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2013 1.64
7 Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014 1.61
8 Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014 1.52
9 The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 2012 1.37
10 Engineered T-cell therapy shows efficacy in blood cancer. Nat Biotechnol 2011 1.17
11 Driving CAR T-cells forward. Nat Rev Clin Oncol 2016 1.09
12 Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010 0.99
13 Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol 2013 0.98
14 CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol 2015 0.95
15 Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014 0.86
16 Immunotherapy for pediatric leukemia. Front Oncol 2013 0.84
17 Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012 0.84
18 Genetically engineered T cells for the treatment of cancer. J Intern Med 2013 0.83
19 Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol 2015 0.82
20 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
21 Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2011 0.79
22 Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther 2010 0.78
23 Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells 2015 0.78
24 Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther 2015 0.77
25 Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges? Hematol Oncol Clin North Am 2013 0.76
26 Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy. Immunotargets Ther 2015 0.75
27 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
Next 100